Tirzepatide shows superior weight loss and glycemic control compared to Dulaglutide.
Guideline-Based Recommendations
Diagnosis
Assess cardiovascular risk in patients with type 2 diabetes.
Management
Consider GLP-1 receptor agonists like Tirzepatide or Dulaglutide for patients with type 2 diabetes and cardiovascular disease.
Monitoring & Follow-up
Regularly monitor blood glucose levels and cardiovascular health.
Risks
Monitor for gastrointestinal side effects and potential pancreatitis.
Patient & Prescribing Data
Tirzepatide is typically initiated at a dose of 2.5 mg once weekly, with potential escalation to 5 mg, 7.5 mg, or 10 mg based on tolerance and glycemic control.
Source for dose escalation information: Clinical trial data from SURPASS studies.
Clinical Best Practices
Individualize treatment based on patient preferences, comorbidities, and risk factors.
by Steven E. Nissen, Kathy Wolski, David D’Alessio, Govinda Weerakkody, Jacek Kiljanski, Russell J. Wiese, Imre Pavo, Bertrand Cariou, Stephen J. Nicholls
The proposed framework classified 30% of patients as high or extreme risk, compared with 12% classified as having severe or greater tricuspid regurgitation under established grading schemes.
Advanced heart failure and transplant cardiologist Sanjeev Kumar Gulati, M.D., FACC, has joined Baptist Health Heart & Vascular Care, and will serve as executive deputy director and system chief of cardiovascular medicine
